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Right Ventricular Function Evaluated by Tricuspid Annular
Plane Systolic Excursion Predicts Cardiovascular Death in the
General Population
Daniel Modin, MB, Rasmus Møgelvang, MD, PhD, Ditte Madsen Andersen, MD; Tor Biering-Sørensen, MD, PhD, MPH
Background-—Cardiovascular disease remains a leading cause of death. Right ventricular (RV) function is a strong predictor of
outcome in many cardiovascular diseases, but its signiﬁcance is often neglected. Little is known about the prognostic value of RV
systolic function in the general population. Therefore, we aimed to determine the prognostic value of RV systolic function,
evaluated by tricuspid annular plane systolic excursion (TAPSE), in predicting cardiovascular death (CVD) in the general population.
Methods and Results-—A total of 1039 participants from the general population without heart failure or atrial ﬁbrillation had an
echocardiogram performed and TAPSE measured. The end point was CVD. During a median follow-up of 12.7 years (interquartile
range, 12.0–12.9 years), 69 participants (6.6%) experienced CVD, whereas 162 participants (15.6%) experienced non-CVD.
Decreasing RV systolic function, assessed as TAPSE, was a univariable predictor of CVD (hazard ratio, 1.13; 95% CI, 1.07–1.20;
P<0.001, per 1-mm decrease). TAPSE remained an independent predictor of CVD after adjusting for clinical and echocardiographic
parameters (hazard ratio, 1.08; 95% CI, 1.01–1.15; P=0.017, per 1-mm decrease). Furthermore, in net reclassiﬁcation analysis,
decreasing RV systolic function, assessed as TAPSE, signiﬁcantly improved risk classiﬁcation with respect to CVD when added to
established cardiovascular risk factors from the Systematic Coronary Risk Evaluation chart or a modiﬁed version of the American
Heart Association/American College of Cardiology Pooled Cohort Equation. Decreasing RV systolic function, assessed as TAPSE,
did not predict non-CVD, indicating speciﬁcity for CVD.
Conclusions-—RV systolic function, as assessed by TAPSE, is associated with CVD in the general population. In the general
population, assessment of RV systolic function may provide novel prognostic information about the risk of CVD. ( J Am Heart
Assoc. 2019;8:e012197. DOI: 10.1161/JAHA.119.012197.)
Key Words: cardiovascular death • cardiovascular risk • general population • prognosis • right ventricle • right ventricle
echocardiography • tricuspid annular plane systolic excursion
T o this day, cardiovascular disease remains the leadingcause of death.1 Currently, methods for predicting
cardiovascular risk in the general population rely on old and
simple risk models.2 The European Society of Cardiology has,
in a recent position statement, emphasized that current risk
scores, such as the SCORE risk chart3 and the American
College of Cardiology (ACC)/American Heart Association
(AHA) Pooled Cohort Equation,4 are useful but insufﬁcient for
predicting cardiovascular risk in the general population.5 One
size does not ﬁt all. Personalized medicine in cardiology
practice can be viewed as a continuum in which new
technologies are continuously incorporated into clinical
practice. A feasible method of collecting a large amount of
personalized information on cardiac structure and function
may be echocardiography. However, before this information
can be used to personalize risk prediction in the general
population, the incremental prognostic value of individual
parameters must be thoroughly tested and validated.2
The right ventricle (RV) has often been coined “the
forgotten chamber.”6 RV dysfunction is an established
predictor of morbidity and mortality in both cardiovascular
and respiratory diseases, including heart failure (HF),7
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myocardial infarction,8 primary pulmonary hypertension,9 and
chronic obstructive pulmonary disease.10 Chronic lung dis-
ease, such as chronic obstructive pulmonary disease, can
lead to hypoxemic vasoconstriction and destruction of
pulmonary capillary beds, which increases pulmonary circu-
latory resistance and, thus, RV afterload. Consequently, in
patients with chronic obstructive pulmonary disease, RV
systolic dysfunction is a marker of poor prognosis.10 In
addition, the RV is also directly affected by the downstream
left ventricular (LV) ﬁlling pressure as a result of circulatory
coupling and RV function is impaired in conditions of diastolic
dysfunction, such as in HF with preserved ejection fraction.11
Diastolic dysfunction is a strong predictor of adverse
cardiovascular outcome in the general population.12 Cur-
rently, the prognostic value of RV systolic function, quantiﬁed
by echocardiography, in predicting cardiovascular death
(CVD) and other cardiovascular outcomes in the general
population is largely unknown.
This study sought to investigate the prognostic value of an
easily obtainable measure of RV systolic function, such as the
tricuspid annular plane systolic excursion (TAPSE), in predict-
ing cardiovascular mortality in the general population.
Methods
Data Availability
The data, analytic methods, and study materials will not be
made available to other researchers for purposes of repro-
ducing the results or replicating the procedure. Because this
study uses data from human subjects, the data and everything
pertaining to them are governed by the Danish Data
Protection Agency and can only be made available to any
additional researchers if a formal request is ﬁled with the
Danish Authorities.
Study Sample
The present study sample is an echocardiographic substudy of
the CCHS (Copenhagen City Heart Study), a longitudinal
cohort study designed to study cardiovascular risk factors.
The population has previously been described in detail.13 The
population is based in and around the Copenhagen city area.
In the fourth round of examination, participants were
allocated for echocardiography in a random manner. At ﬁrst,
2221 participants had an echocardiogram, including tissue
Doppler imaging, performed. For this substudy, 67 partici-
pants were excluded because of prevalent HF or atrial
ﬁbrillation. Because the echocardiograms were obtained in
2001 to 2003 using a protocol not speciﬁcally designed for
RV analysis, 1115 participants had to be excluded because of
inadequate image quality for measurement of TAPSE. Most of
these exclusions were because of the lateral tricuspid annulus
area being outside of the imaging plane during part of the
cardiac cycle, making tracking of the systolic motion nonfea-
sible, or because of acoustic shadowing of the lateral tricuspid
annulus. A comparison of excluded participants with included
participants is available in Table S1. This left 1039 partic-
ipants for inclusion into the present study.
Ethics
Written consent was collected from all participants, and the
study design was approved by a regional scientiﬁc ethics
committee. Finally, the study complies with the Second
Declaration of Helsinki.
General Health Examination
Participants were subject to a general health examination,
consisting of a questionnaire and a physical examination. In
addition, participants had their lung function assessed by
spirometry. The presence of obstructive lung function at
baseline was deﬁned as a forced expiratory volume in 1
second (FEV1) divided by the forced vital capacity of <0.7.
Deﬁnitions of diabetes mellitus, hypertension, and preva-
lent ischemic heart disease have previously been described.13
Echocardiography
All echocardiograms were obtained using Vivid 5 ultrasound
machines (GE Healthcare, Horten, Norway) by 3 experienced
sonographers with a 2.5-MHz transducer. All examinations
underwent ofﬂine analysis by another experienced investiga-
tor. This investigator was blinded to all outcome and clinical
Clinical Perspective
What Is New?
• No studies have investigated the prognostic value of right
ventricular systolic function, assessed as tricuspid annular
plane systolic excursion, in a large cohort of individuals from
the general population.
• In our study, tricuspid annular plane systolic excursion was
an independent predictor of cardiovascular death in indi-
viduals from the general population; this was true even in
people with normal left ventricular ejection fraction (≥60%).
What Are the Clinical Implications?
• Tricuspid annular plane systolic excursion may facilitate
early identiﬁcation of individuals at high risk of cardiovas-
cular death, allowing for prompt intervention and intensiﬁed
follow-up.
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data. The ofﬂine analysis was done using commercially
available software (EchoPac, version 8; GE Healthcare).
Conventional Echocardiography
The wall motion score index was assessed using the 16-
segment model and used to calculate the LV ejection fraction
(LVEF).14 TAPSE was measured in the lateral tricuspid annulus
from the apical 4-chamber view using an M-mode cursor. LV
hypertrophy was deﬁned as directed in current guideliens.14
Peak early and late diastolic inﬂow velocities were derived
from mitral inﬂow patterns using pulsed-wave Doppler
between the mitral leaﬂet tips in the apical position. These
were used to calculate early/late diastolic inﬂow velocity and
to measure deceleration time of the E-wave.
Color Tissue Doppler Imaging
Color tissue Doppler imaging velocity tracings, with the range
gate positioned in the lateral and septal mitral annulus of the
4-chamber view, were obtained. These were used to deter-
mine the peak systolic tissue velocity (s0), the peak early
diastolic velocity (e0), and the peak late diastolic velocity.
Then, the ratio of the E wave/e0 (E/e0) was calculated.
Follow-Up and Outcome
The participants were enrolled in 2001 to 2003. They were
followed up until time to death or until October 2014. The end
point of this study was CVD. When assessing the outcome of
CVD, non-CVD (NCD) was treated as a censoring event. A
secondary end point was NCD. When assessing the outcome
of NCD, CVD was treated as a censoring event. The Danish
National Cause of Death Registry and the Danish National
Board of Health’s National Patient Registry were used to
obtain follow-up data. Follow-up data were retrieved using the
International Classiﬁcation of Diseases, Tenth Revision (ICD-
10), codes. CVD was deﬁned as ICD-10 codes I00 to I99. NCD
was deﬁned as ICD-10 codes not equal to I00 to I99. Follow-
up was 100%.
Statistical Analysis
Statistical analysis was performed using STATA 13.0 for Mac
OS. In Table 1, continuous variables, exhibiting gaussian
distribution, were compared using the Student t test and
reported as meanSD. In the case of a nongaussian
distribution, continuous variables were compared using the
Wilcoxon rank-sum test and reported as median with
interquartile ranges. Proportions were compared using the
v2 test. In Table 2, linear regression of means was used to
analyze trend over tertiles of TAPSE. In Table 3, univariable
and multivariable Cox regressions were used to assess the
prognostic value of TAPSE in predicting CVD and NCD. The
number of events per adjusting variable was set to 5,15
leaving room for a maximum of 14 adjusting variables in the
ﬁnal multivariable model (69 CVDs at follow-up). Statistical
signiﬁcance was deﬁned as P≤0.05 in 2-sided t tests. In the
Figure, Poisson regression, using robust standard errors to
control for overdispersion, was used to estimate incidence
rates of CVD as a function of TAPSE. In Table S2, multivari-
able linear regression analysis, adjusted for established
cardiovascular risk factors and comorbidities, was used to
determine associations between TAPSE and other echocar-
diographic parameters (Table S2). In Table S3, net reclassi-
ﬁcation improvement16 analysis was used to assess the
incremental prognostic value of TAPSE when added to
established cardiovascular risk factors in predicting CVD
(Table S3). In these analyses, we chose to assess the
incremental prognostic value of adding TAPSE to risk factors
from the SCORE risk chart3 because this model is used in
daily clinical practice in Denmark. In addition, we also
considered the AHA/ACC Pooled Cohort equation4 (excluding
race because the inhabitants of Denmark are mainly white)
because this model is recommended in the new 2017 ACC/
AHA guidelines on the management of hypertension17 and
also the Framingham risk score because of its widespread
use and credibility.18
Results
Follow-Up and Outcome
The median follow-up time was 12.7 years (interquartile
range, 12.0–12.9 years), and follow-up was 100%. The
primary end point of CVD was reached by 69 participants
(6.6%). A total of 162 participants reached the secondary end
point of NCD (15.6%).
Baseline Characteristics, According to Exclusion
Status
Excluded participants were older, were more hypertensive,
and had a larger body mass index (Table S1). They were also
more likely to be men and to have higher heart rates
(Table S1).
Baseline Characteristics of the Population,
According to CVD
Participants who experienced CVD were older and more
hypertensive (Table 1). Furthermore, participants who expe-
rienced CVD displayed a higher prevalence of comorbidities
(Table 1). With regard to echocardiography, participants who
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Table 1. Population Stratiﬁed According to CVD and NCD
Variable All Participants No CVD CVD P Value* NCD P Value†
Demographics
No. 1039 970 69 162
Age, y 57.3 (16.0) 56.0 (15.7) 75.2 (8.3) <0.001 70.7 (11.2) <0.001
Men 416 (40.0) 382 (39.4) 34 (49.3) 0.11 76 (46.9) 0.042
Clinical characteristics
Systolic blood
pressure, mm Hg
133.6 (22.9) 132.3 (22.3) 152.8 (23.3) <0.001 144.6 (21.5) <0.001
Diastolic blood
pressure, mm Hg
77.6 (12.3) 77.3 (11.9) 82.5 (16.1) <0.001 78.0 (11.6) 0.72
Pulse pressure, mm Hg 55.9 (18.2) 54.9 (17.4) 70.7 (23.1) <0.001 66.7 (18.3) <0.001
Mean arterial pressure, mm Hg 96.1 (14.2) 95.4 (13.9) 105.8 (15.6) <0.001 100.0 (13.) <0.001
Hypertension 392 (39.0) 341 (36.3) 51 (79.7) <0.001 105 (65.6) <0.001
Smoking 352 (35.4) 330 (35.5) 22 (33.8) 0.79 67 (42.1) 0.049
Body mass index, kg/m2 25.4 (3.9) 25.3 (3.8) 26.6 (4.7) 0.008 25.7 (3.9) 0.39
Diabetes mellitus 96 (9.6) 85 (9.0) 11 (17.5) 0.028 22 (13.8) 0.050
Heart rate, BPM 67 (1) 66 (11) 68 (12) 0.45 69 (12) <0.001
Ischemic heart disease 45 (4.5) 40 (4.3) 5 (7.8) 0.02 17 (10.6) 0.008
Acute myocardial infarction 16 (1.6) 14 (1.5) 2 (3.1) 0.31 9 (5.6) 0.009
FEV1, L 2.81 (0.98) 2.87 (0.97) 2.04 (0.65) <0.001 2.16 (0.75) <0.001
FVC, L 3.65 (1.17) 3.71 (1.17) 2.81 (0.81) <0.001 2.98 (0.90) <0.001
FEV1/FVC 0.77 (0.08) 0.77 (0.08) 0.73 (0.11) <0.001 0.72 (0.10) <0.001
Obstructive lung function 167 (16.1) 146 (15.1) 21 (30.4) <0.001 50 (31.0) <0.001
Laboratory work
Total cholesterol, mmol/L 5.58 (1.16) 5.56 (1.16) 5.83 (1.06) 0.07 5.75 (0.11) 0.052
Plasma pro-BNP, pmol/L 15 (7–28) 15 (7–26) 33 (14–64) <0.001 20.5 (8.5–40) <0.001
eGFR, mL/min per 1.73 m2 73 (20) 74 (20) 65 (21) <0.001 68 (21) <0.001
Echocardiography
TAPSE, mm 26 (5) 27 (5) 24 (5) 0.001 26 (4) 0.004
LVEF, % 59.8 (1.3) 59.8 (1.2) 59.4 (1.9) 0.048 59.5 (2.2) 0.01
LV hypertrophy 248 (23.9) 218 (22.5) 30 (43.5) <0.001 60 (37.0) <0.001
LVIDd, cm 4.8 (0.5) 4.8 (0.5) 4.7 (0.5) 0.36 4.6 (0.6) <0.001
LVMI, g/m2 84.3 (20.7) 83.1 (19.3) 102.4 (29.9) <0.001 88.7 (20.3) 0.011
Left atrium dimension, cm 3.4 (.4) 3.4 (0.4) 3.6 (0.4) <0.001 3.5 (0.4) 0.003
E/e0 10.7 (4.2) 10.4 (4.0) 14.9 (50) <0.001 12.8 (5) <0.001
E/A 1.12 (0.43) 1.13 (0.43) 0.89 (0.35) <0.001 0.91 (0.37) <0.001
Deceleration time, ms 166 (41) 165 (39) 186 (56) <0.001 175 (51) 0.005
s0, cm/s 6.0 (1.2) 6.0 (1.2) 5.3 (1.2) <0.001 5.5 (1.1) <0.001
e0, cm/s 7.4 (2.7) 7.6 (2.6) 4.8 (1.5) <0.001 5.7 (1.9) <0.001
a0, cm/s 6.5 (1.9) 6.5 (1.9) 6.8 (1.9) 0.20 7.3 (1.7) <0.001
Data are given as number, number (percentage), or mean (SD). a0 Indicates peak late diastolic velocity; BPM, beats per minute; CVD, cardiovascular death; e0 , peak early diastolic
velocity; E/A, early/late diastolic inﬂow velocity; E/e0 , ratio of the E wave/e0 ; eGFR, estimated glomerular ﬁltration rate; FEV1, forced expiratory volume in 1 second; FVC, forced
vital capacity; LV, left ventricular; LVEF, LV ejection fraction; LVIDd, LV inner diameter at end diastole; LVMI, LV mass index; NCD, non-CVD; pro-BNP, pro-B-type natriuretic peptide;
s0 , peak systolic tissue velocity; TAPSE, tricuspid annular plane systolic excursion.
*Comparing participants experiencing CVD with participants who did not experience CVD.
†Comparing participants who experienced death from noncardiovascular causes with participants who did not experience death from noncardiovascular causes.
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Table 2. Population Stratiﬁed According to Tertiles of TAPSE
Variable All Participants
Worse ? Better
P Value for
Trend
First Tertile,
TAPSE <24 mm
Second Tertile,
24 mm < TAPSE <28 mm
Third Tertile,
TAPSE >28 mm
Demographics
No. 1039 349 347 343
Age, y 57.3 (16.0) 61.0 (16.1) 56.0 (15.6) 54.9 (15.8) <0.001
Men 416 (40.0) 137 (39.3) 130 (38.0) 149 (42.8) 0.34
Clinical characteristics
Systolic blood
pressure, mm Hg
133.6 (22.9) 135.9 (22.9) 132.9 (23.5) 132.1 (22.2) 0.029
Diastolic blood pressure, mm Hg 77.6 (12.3) 78.6 (12.3) 77.2 (11.6) 77.2 (12.9) 0.14
Pulse pressure, mm Hg 55.9 (18.2) 57.2 (18.5) 55.8 (19.5) 54.8 (16.6) 0.09
Mean arterial pressure, mm Hg 96.1 (14.2) 97.4 (14.2314) 95.6 (13.7) 95.2 (14.6) 0.046
Hypertension 392 (39.0) 148 (44.4) 131 (39.3) 112 (33.4) 0.003
Smoking 352 (35.4) 125 (37.8) 114 (34.9) 113 (33.5) 0.25
Body mass index, kg/m2 25.4 (3.9) 25.3 (4.0) 25.5 (4.0) 25.5 (3.7) 0.32
Diabetes mellitus 96 (9.6) 33 (9.9) 44 (13.3) 19 (5.6) 0.06
Heart rate, BPM 67 (1) 69 (12) 66 (11) 65 (11) <0.001
Ischemic heart disease 45 (4.5) 28 (8.4) 4 (1.2) 13 (3.8) 0.004
Acute myocardial infarction 16 (1.6) 11 (3.3) 2 (0.6) 3 (0.9) 0.013
FEV1, L 2.81 (0.98) 2.55 (0.91) 2.88 (0.96) 3.02 (0.99) <0.001
FVC, L 3.65 (1.17) 3.34 (1.07) 3.71 (1.19) 3.90 (1.19) <0.001
FEV1/FVC 0.77 (0.08) 0.76 (0.09) 0.77 (0.08) 0.77 (0.08) 0.09
Obstructive lung function 167 (16.1) 64 (18.3) 54 (15.8) 49 (14.1) 0.31
Laboratory work
Total cholesterol, mmol/L 5.58 (1.16) 5.6 (1.2) 5.6 (1.2) 5.5 (1.1) 0.22
Plasma pro-BNP, pmol/L 15 (7–28) 17 (8–30) 15 (8–29) 14 (7–25.5) 0.041
eGFR, mL/min per 1.73 m2 73 (20) 72 (20) 72 (22) 75 (18) 0.043
Echocardiography
TAPSE, mm 26 (5) 22 (2) 26 (1) 32 (3) N/A
LVEF, % 59.8 (1.3) 59.7 (1.5) 59.8 (1.5) 59.9 (0.7) 0.039
LV hypertrophy 248 (23.9) 93 (26.6) 81 (23.7) 74 (21.3) 0.10
LVIDd, cm 4.8 (0.5) 4.6 (0.5) 4.8 (0.5) 4.8 (0.5) <0.001
LVMI, g/m2 84.3 (20.7) 85.0 (22.4) 82.7 (18.5) 85.2 (20.8) 0.89
Left atrium dimension, cm 3.4 (0.4) 3.4 (0.4) 3.4 0.4) 3.4 (0.4) 0.10
E/e0 10.7 (4.2) 11.6 (4.7) 10.3 (3.7) 10.1 (4.1) <0.001
E/A 1.12 (0.43) 1.05 (0.43) 1.15 (0.41) 1.15 (0.44) 0.002
Deceleration time, ms 166 (41) 170 (43) 162 (38) 166 (41) 0.29
s0, cm/s 6.0 (1.2) 5.7 (1.2) 6.0 (1.1) 6.2 (1.3) <0.001
e0, cm/s 7.4 (2.7) 6.6 (2.5) 7.6 (2.6) 8.0 (2.8) <0.001
a0, cm/s 6.5 (1.9) 6.6 (2.0) 6.4 (1.8) 6.5 (1.9) 0.28
Data are given as number, number (percentage), or mean (SD). a0 Indicates peak late diastolic velocity; BPM, beats per minute; e0 , peak early diastolic velocity; E/A, early/late diastolic
inﬂow velocity; E/e0 , ratio of the E wave/e0 ; eGFR, estimated glomerular ﬁltration rate; FEV1, forced expiratory volume in 1 second; FVC, forced vital capacity; LV, left ventricular; LVEF, LV
ejection fraction; LVIDd, LV inner diameter at end diastole; LVMI, LV mass index; N/A, not applicable; pro-BNP, pro-B-type natriuretic peptide; s0 , peak systolic tissue velocity; TAPSE,
tricuspid annular plane systolic excursion.
DOI: 10.1161/JAHA.119.012197 Journal of the American Heart Association 5
RV Function in the General Population Modin et al
O
R
IG
IN
A
L
R
E
S
E
A
R
C
H
D
ow
nloaded from
 http://ahajournals.org by on September 23, 2019
experienced CVD displayed lower values of TAPSE, LVEF,
early/late diastolic inﬂow velocity, s0, and e0 (Table 1). They
also displayed higher values of LV mass index, left atrium
dimension, E/e0, and deceleration time of the E-wave
(Table 1). Finally, participants who experienced CVD had
lower rates of FEV1, forced vital capacity, FEV1/forced vital
capacity and a higher prevalence of obstructive lung function
at baseline (Table 1).
Baseline Characteristics, According to Tertiles of
TAPSE
At baseline, decreasing RV systolic function, assessed as
TAPSE, was associated with older age, higher systolic blood
pressure, higher heart rate, higher pro-B-type natriuretic
peptide (pro-BNP), and decreasing values of estimated
glomerular ﬁltration rate (Table 2). Decreasing RV systolic
function was also associated with increasing prevalence of
hypertension, ischemic heart disease, and previous acute
myocardial infarction (Table 2). Furthermore, decreasing RV
systolic function, as determined by TAPSE, was associated
with decreasing values of LVEF, LV inner diameter at end
diastole, early/late diastolic inﬂow velocity, s0, and e0
(Table 2). Decreasing RV systolic function was also associ-
ated with increasing values of E/e0 (Table 2). Last, decreasing
RV systolic function was associated with decreasing values of
FEV1 and forced vital capacity (Table 2).
Association of RV Systolic Function With Other
Echocardiographic Parameters
After adjusting for differences in clinical risk factors and
comorbidities, decreasing RV function, as determined by
TAPSE, was signiﬁcantly associated with decreasing s0, e0, and
left atrium dimension (Table S2).
Prognostic Value of RV Function, Determined by
TAPSE, in Predicting CVD
The risk of CVD increased signiﬁcantly with decreasing RV
function, as assessed by TAPSE (Table 3, Figure). Participants
in the ﬁrst (worst) tertile of RV function, as determined by
TAPSE, displayed an 3.5 times greater risk of CVD when
compared with participants in the third (best) tertile (ﬁrst
versus third tertile: hazard ratio [HR], 3.49; 95% CI, 1.87–
6.53; P<0.001). A nonlinear relationship between decreasing
RV systolic function, determined by TAPSE, and the risk of
CVD was found (Figure). TAPSE values above 24 mm did not
appear to be associated with an increased risk of experiencing
CVD (Figure). However, the risk of CVD appeared to increase
with decreasing values of TAPSE for TAPSE values below
24 mm (Figure).
In a multivariable model adjusting for age, sex, systolic
blood pressure, hypertension, cholesterol, smoking, and
diabetes mellitus, decreasing RV function, as determined by
TAPSE, was an independent predictor of CVD (Table 3, model
1). In a ﬁnal multivariable model adjusting for the same
variables as in model 1 with the addition of LV mass index, LV
inner diameter at end diastole, LVEF, left atrium dimension,
pro-BNP, E/e0, and prevalent ischemic heart disease, RV
function by TAPSE remained an independent predictor of CVD
(Table 3, model 2). This relationship persisted with additional
adjustment for obstructive lung function (HR, 1.08; 95% CI,
1.01–1.14; P=0.017 per 1-mm decrease). Similarly, TAPSE
remained an independent predictor of outcome when the ﬁnal
multivariable model was additionally adjusted for estimated
glomerular ﬁltration rate (HR, 1.08; 95% CI, 1.01–1.15;
P=0.017 per 1-mm decrease). Even when conﬁning our ﬁnal
multivariable model to participants with normal RV systolic
function (TAPSE ≥17 mm), RV function by TAPSE remained an
independent predictor of CVD (model 2: HR, 1.07; 95% CI,
1.00–1.15; P=0.046 per 1-mm decrease). Similar results were
Table 3. Univariable and Multivariable Cox Regression to Assess the Prognostic Value of TAPSE in Predicting Cardiovascular
Outcomes in the General Population
TAPSE, per 1-mm Decrease
CVD (n=69) NCD (n=162)
Hazard Ratio (95% CI) P Value Hazard Ratio (95% CI) P Value
Unadjusted
1.13 (1.07–1.20) <0.001 1.06 (1.03–1.10) <0.001
Model 1
1.08 (1.02–1.14) 0.005 1.04 (1.00–1.07) 0.051
Model 2
1.08 (1.01–1.15) 0.017 1.03 (0.98–1.07) 0.19
Model 1 is adjusted for age, sex, systolic blood pressure, hypertension, cholesterol levels, smoking, and diabetes mellitus. Model 2 is adjusted for the same variables as model 1 with the
addition of left ventricular mass index, left ventricular internal diameter at end diastole, left ventricular ejection fraction, left atrium dimension, pro-B-type natriuretic peptide, ratio of the E
wave/peak early diastolic velocity, and prevalent ischemic heart disease. CVD indicates cardiovascular death; NCD, non-CVD; TAPSE, tricuspid annular plane systolic excursion.
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found when conﬁning our analysis to participants with normal
RV systolic function (TAPSE ≥17 mm) and normal LV systolic
function (LVEF ≥60%) (model 2: HR, 1.08; 95% CI, 1.01–1.16;
P=0.031 per 1-mm decrease).
Incremental Prognostic Value of RV Function in
Predicting CVD in the General Population
Adding the presence of decreased RV systolic function (deﬁned
as the lower tertile of TAPSE values, TAPSE <24 mm) to
established cardiovascular risk factors from the SCORE risk
chart, a modiﬁed version of the AHA/ACC Pooled Cohort
Equation, or a modiﬁed version of the Framingham Risk Score
signiﬁcantly improved risk classiﬁcation with respect to CVD
(Table S3). In contrast, LVEF, E/e0, and pro-BNP did not
signiﬁcantly improve risk classiﬁcation of individuals from the
general population with respect to CVD (Table S3).
Discussion
In this study, we found RV systolic function, as assessed by
TAPSE, to be an independent predictor of CVD in the general
population. Furthermore, assessing RV systolic function
added incremental prognostic value in predicting CVD in the
general population in addition to established cardiovascular
risk factors from the SCORE risk chart and a modiﬁed version
of the AHA/ACC Pooled Cohort Equation. In contrast, LVEF,
E/e0, and pro-BNP levels did not contribute with incremental
prognostic information. To our knowledge, this is the largest
study to date assessing the prognostic value of RV systolic
function in predicting cardiovascular outcomes in the general
population with long-term follow-up.
TAPSE and RV Systolic Function
Assessment of the RV systolic function may be beneﬁcial for
risk stratiﬁcation of individuals from the general population.
This may be because of TAPSE’s simplicity, ease of measure-
ment, and good reproducibility.19 It does not require state-of-
the art image quality or high-frame rate conditions for optimal
measurement,19 as is the case for other measures of RV
systolic function, such as 2-dimensional speckle tracking of
the RV free wall.19 In addition, it can often be hard to acquire
high-quality images of the entire RV free wall, whereas
imaging only the RV base and tricuspid annular plane is much
more feasible. Despite its simplicity, TAPSE correlates well
Figure. Tricuspid annular plane systolic excursion (TAPSE) and long-term risk of cardiovascular death in
the general population. The ﬁgure displays the unadjusted incidence rate of cardiovascular death per
100 person-years as a function of TAPSE. Test for overall relationship, P<0.001. Test for nonlinearity,
P=0.008. Dashed lines represent 95% CIs. The vertical red line represents the cutoff for the lower tertile of
TAPSE values.
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with RV ejection fraction determined by radionucleotide
angiography.19,20
Normal RV Systolic Function in the General
Population
Current guidelines deﬁne the normal range of RV systolic
function determined by TAPSE in the general population as a
meanSD of 243.5 mm.14 In our sample from the general
population, values of TAPSE were higher (mean, 26 mm; SD,
5 mm). The reason for the higher values of TAPSE seen in this
study is unclear. In current guidelines, abnormal RV systolic
function is deﬁned as TAPSE <17 mm.14 In our study, a
TAPSE of ≤17 mm was signiﬁcantly associated with a higher
risk of CVD, as shown by the Figure. However, the Figure also
revealed that the risk of CVD increases with decreasing values
of TAPSE already once TAPSE is below 24 mm, which is
currently considered within the normal range.14 Furthermore,
we show that participants in the lower tertile of RV systolic
function, as determined by TAPSE (TAPSE <24 mm), are at an
increased risk of experiencing CVD. Also, in our ﬁnal
multivariable model adjusting for clinical and echocardio-
graphic parameters, RV systolic function by TAPSE remained
an independent predictor of CVD, even when conﬁning our
analysis to participants with a normal TAPSE (TAPSE ≥17 mm)
and a normal LV systolic function (LVEF ≥60%). These ﬁndings
suggest that deﬁning abnormal RV systolic function as TAPSE
<17 mm may be conservative. However, more research is
needed to validate our ﬁndings.
Prognostic Value of RV Systolic Function in the
General Population
At the current moment, little evidence exists on the prognostic
value of RV systolic function in the general population. Kawut
et al evaluated RV systolic function in the MESA (Multi-Ethnic
Study of Atherosclerosis), assessed as RV ejection fraction by
cardiac magnetic resonance imaging, and found that RV
systolic function was not signiﬁcantly associated with a
composite outcome of HF and CVD.21 However, differences in
study populations and follow-up duration make direct com-
parisons with our study difﬁcult. Kawut et al21 studied a
sample composed of 40% whites, 30% blacks, 20% Hispan-
ics, and 10% Chinese, whereas our study sample was
composed almost entirely of whites. In addition, in their study,
all participants with cardiovascular disease were excluded,
whereas we only excluded participants with HF; and the
prevalence of cigarette smoking at baseline was much lower in
their study compared with ours (12% versus 35%). Thus, when
compared with our study sample, Kawut et al21 studied an
ethnically diverse, healthier population, and this may partly
explain the differences between our results. In addition, our
follow-up duration was over twice the follow-up duration in the
study by Kawut et al21 (mean, 5.8 years, versus median,
12.7 years). This could also contribute to the difference
between our results because it is possible that RV systolic
function may be particularly associated with long-term
outcome in the general population.
In our study, RV function, determined by TAPSE, was
superior to E/e0, pro-BNP, and LVEF in predicting CVD in the
general population. Decreased RV systolic function is often a
marker of advanced and progressed disease in HF. In the
absence of cardiovascular disease, with normal pulmonary
vasculature, the LV is capable of sustaining the circulatory
needs of the body, even without RV function.22 As the LV
diastolic or systolic function becomes impaired, increasing
levels of RV compensation are needed to sustain cardiac
output and minimize venous congestion.23 Thus, right-sided
heart function is adversely affected by deteriorating LV
function through circulatory coupling. Accordingly, it is known
that LV diastolic dysfunction may cause pulmonary hyperten-
sion.11,24 RV systolic function, assessed by TAPSE, is
decreased in pulmonary hypertension and is a powerful
predictor of outcome.25 Hence, it is possible that RV systolic
function, assessed as TAPSE, is an integrated marker of LV
diastolic dysfunction, a condition that is relatively common in
the aging general population26 and is associated with
cardiovascular morbidity and mortality.12 This is supported
by our results because TAPSE was signiﬁcantly associated
with e0 and left atrial size, both of which reﬂect diastolic
function. Also, LV systolic function is a signiﬁcant determinant
of RV systolic function through mechanical interventricular
dependence.27 In our study, decreasing RV systolic function,
as determined by TAPSE, was signiﬁcantly associated with
decreasing systolic LV function, as determined by s0 after
adjustment for differences in clinical risk factors. Because s0
has been previously shown to predict CVD in the general
population,28 some of the prognostic value of RV function with
respect to CVD may also be because of its relation to LV
systolic performance through interventricular dependence.
However, although we adjusted for systolic function as
determined by LVEF, RV function, determined by TAPSE,
remained a strong predictor of CVD.
HF is a signiﬁcant contributor to CVD.29 Interestingly, RV
systolic dysfunction has been found to be more frequent in
idiopathic dilated cardiomyopathy when compared with
ischemic cardiomyopathy.30 This indicates that RV systolic
dysfunction may be associated with generalized myocardial
disease, independent of ischemic disease. Thus, some of the
prognostic value of RV function, determined by TAPSE, in
predicting CVD in the general population may be because of
its ability to detect early cardiomyopathy independent of LV
dysfunction attributable to ischemic and hypertensive heart
disease. This may also explain part of why RV systolic function
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remained an independent predictor of CVD, even after
adjusting for diastolic function (as determined by E/e0, pro-
BNP, and left atrial size) in our ﬁnal multivariable model.
Future Perspectives and Limitations
Little evidence about the prognostic value of RV systolic
function in predicting CVD in the general population with long-
term follow-up exists. Our results should be considered
exploratory and hypothesis generating. Strengths of the
present study are a large sample of individuals from the
general population and long-term complete follow-up. A
limitation of the present study is the lack of information on
RV systolic pressure. It would be interesting to assess
whether the prognostic value of RV systolic function is
independent of RV afterload. Unfortunately, information on RV
systolic pressure was not available in this study. Another
limitation is the large number of patients who had to be
excluded because of inadequate image quality for measuring
TAPSE, although measurement of TAPSE is highly feasible in
most patients.19 Because the echocardiograms were obtained
in 2001 to 2003 using less sophisticated hardware than what
is available today, and because the original image protocol
was not speciﬁcally designed to assess RV function, the
number of patients who had to be excluded was signiﬁcantly
higher than what would be expected using contemporary
equipment and a protocol designed to optimize RV imaging.
Because excluded participants were signiﬁcantly older, had a
higher blood pressure, and had a higher body mass index, this
may potentially have introduced a selection bias. However,
although many high-risk patients were excluded because of
inadequate images for the measurement of TAPSE, we still
found signiﬁcant associations between TAPSE and CVD,
despite rigorous adjustment for clinical, echocardiographic,
and lung function parameters. Nonetheless, if a selection bias
was introduced, this could affect the generalizability of our
results and, therefore, our results should be conﬁrmed in
future studies.
Conclusion
RV systolic function, as assessed by TAPSE, is associated with
CVD in the general population. In the general population,
assessment of RV systolic function may provide novel
prognostic information about the risk of CVD.
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 Table S1. Comparison of participants included in the study with participants excluded due to 
either heart failure, atrial fibrillation or suboptimal image quality for measurement of tricuspid 
annular plane systolic excursion.  
 
Demographics Study sample    Excluded participants P-value 
N  1039 1182  
Age (years) 57.2 (16.1) 60.3 (15.9) <0.001 
Male  398 (39.6%) 535 (45.0%) 0.010 
Clinical Characteristics    
Systolic blood pressure (mmHG) 133.5 (23.0) 138.1 (22.2) <0.001 
Diastolic blood pressure (mmHG) 77.6 (12.3) 78.8 (12.0) 0.023 
Pulse Pressure (mmHG) 55.9 (18.2) 59.3 (18.2) <0.001 
Mean arterial pressure (mmHG) 96.1 (14.2) 98.4 (13.7) <0.001 
Hypertension  392 (39.0%) 579 (49.1%) <0.001 
Smoking 352 (35.6%) 314 (31.7%) 0.07 
Body mass index (kg/m2) 25.3 (3.8) 25.8 (4.1) 0.008 
Diabetes Mellitus  96 (9.6%) 141 (11.9%) 0.08 
Heart rate (BPM) 66.5 (11.2) 68.1 (11.8) 0.001 
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 Table S2. Multivariable linear regression analysis to determine associations between TAPSE and other echocardiographic parameters 
in the general population.  
 
 
 Univariable  Multivariable*  
Parameter 
Standardized ß-
coefficient (std error) P-Value  
Standardized ß-
coefficient (std error) P-Value 
LVEF (%) 0.06 (0.01) 0.044 0.05 (0.01) 0.10 
Hypertrophy -0.05 (0.03) 0.08 -0.01 (0.4) 0.79 
LVIDd/BSA (cm) 0.01 (0.06) 0.71 0.02 (0.06) 0.57 
LVMI (g/m2) 0.02 (0.14) 0.59 0.07 (0.01) 0.09 
LAd (cm)  0.07 (0.04) 0.025 0.11 (0.04) 0.002 
E/e’  -0.13 (0.36) <0.001 -0.06 (0.45) 0.15 
E/A  0.11 (0.03) 0.001 0.01 (0.05) 0.76 
DT (ms)  -0.03 (0.37) 0.30 0.03 (0.40) 0.43 
s’ (cm/s) 0.15 (0.01) <0.001 0.11 (0.01) 0.005 
e’ (cm/s) 0.21 (0.01) <0.001 0.26 (0.01) <0.001 
a’ (cm/s) -0.03 (0.01) 0.33 0.05 (0.01) 0.22 
 
 
*The multivariable model is adjusted for age, sex, cholesterol, smoking, systolic blood pressure, hypertension, diabetes, prevalent 
ischemic heart disease.  
TAPSE, tricuspid annular plane systolic excursion; LVEF, left ventricular ejection fraction; LVIDd, left ventricular inner diameter at end 
diastole; LVMI ,left ventricular mass index; LAd, left atrium dimension; DT, deceleration time.   
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 Table S3. Net Reclassification Improvement analysis.  
 
SCORE risk chart Net Reclassification Improvement 
Decreased RV systolic function (TAPSE<24mm) Continuous NRI 0.522, 95% CI 0.072-0.765*    
LVEF Continuous NRI 0.185, 95% CI -0.353-0.528 
E/e’ Continuous NRI -0.078, 95% CI -0.385-0.495 
pro-BNP Continuous NRI -0.186, 95% CI -0.542-0.239 
Modified ACC/AHA Pooled Cohort Equation Net Reclassification Improvement 
Decreased RV systolic function (TAPSE<24mm) Continuous NRI 0.509, 95% CI 0.026-0.757*       
LVEF Continuous NRI 0.236, 95% CI -0.369-0.528 
E/e’ Continuous NRI -0.160,  95% CI -0.416-0.503 
pro-BNP Continuous NRI -0.129,  95% CI -0.498-0.212 
Framingham risk score Net Reclassification Improvement 
Decreased RV systolic function (TAPSE<24mm) Continuous NRI 0.496, 95% CI 0.016-0.757* 
LVEF Continuous NRI 0.265, 95% CI -0.335-0.573 
E/e’ Continuous NRI -0.185, 95% CI -0.451-0.510    
pro-BNP Continuous NRI -0.235, 95% CI -0.519-0.228 
  
  
  
  
 
Net Reclassification Improvement analysis to evaluate incremental prognostic value of adding the presence of decreased RV systolic 
function to established cardiovascular risk factors. Decreased RV systolic function is defined as a TAPSE of less than the cutoff-value for 
the lower tertile of TAPSE values (TAPSE<24mm). SCORE risk chart cardiovascular risk factors are age, sex, cholesterol levels, systolic 
blood pressure and smoking status. The modified ACC/AHA Pooled Cohort Equation risk factors are age, sex, cholesterol levels, systolic 
blood pressure, smoking status, hypertension status and diabetes status (race was not included, since the inhabitants of Denmark are 
mainly white). Framingham risk score risk factors are age, systolic blood pressure, total cholesterol, blood pressure medication, smoking 
and diabetes (HDL cholesterol was not included since this information was not available). RV, right ventricle; TAPSE, tricuspid annular 
plane systolic excursion; LVEF, left ventricular ejection fraction. 
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